Astellas Reports IZERVAY Reduced Vision Decline in GA Patients
NORTHBROOK, Ill., May 12, 2026 Astellas Pharma US announced new clinical findings showing that IZERVAY® (avacincaptad pegol intravitreal solution)...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
NORTHBROOK, Ill., May 12, 2026 Astellas Pharma US announced new clinical findings showing that IZERVAY® (avacincaptad pegol intravitreal solution)...
BERLIN, Germany, and SAN FRANCISCO, Calif., May 6, 2026 Bayer has announced an agreement to fully acquire Perfuse Therapeutics...
PALO ALTO, Calif., Feb. 4, 2026 —Kodiak Sciences Inc. announced that final end-of-study Phase 1b APEX clinical results evaluating...
